吉林省辉南长龙生化药业股份有限公司(“公司”，股份代号：8049)于2026年2月3日认购中国工商银行结构性存款产品，认购金额为人民币1亿元。该产品为保本浮动收益型，投资期限365日，预期年化收益率为2%，产品风险水平很低，认购人无权提前终止或赎回。
公司表示，该笔认购旨在充分利用经营所得的现金盈余，通过提升回报率并维持较高资本流动性和较低风险，从而加强库务管理。公司亦称，此次认购不会对营运资金或日常运作造成影响。
根据香港联合交易所有限公司GEM上市规则第19.22条，公司与中国工商银行的合并认购本金合计人民币2.5亿元，其中至少一项适用百分比率超过5%但低于25%，因此构成须予披露交易，需遵守相关申报及公告规定，但获豁免股东批准要求。董事会认为，该交易公平合理且符合公司及股东整体利益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.